Lenvatinib Good Manufacturer supply High Quality 417716-92-8
- Molecular Formula:C21H19ClN4O4
- Molecular Weight:426.859
- Vapor Pressure:0mmHg at 25°C
- Refractive Index:1.697
- Boiling Point:627.242 °C at 760 mmHg
- PKA:13.09±0.70(Predicted)
- Flash Point:333.144 °C
- PSA：115.57000
- Density:1.469 g/cm3
- LogP:5.23610
Lenvatinib (417716-92-8) Usage
Lenvatinib is an inhibitor of the receptor tyrosine kinases VEGF receptor 2 (VEGFR2) and VEGFR3 (IC50s = 4 and 5.2 nM, respectively). It also inhibits the related kinases VEGFR1, FGFR1, PDGFRα, PDGFRβ and Kit (IC50s = 22, 46, 51, 39, and 100 nM, respectively). Lenvatinib (30 mg/kg, twice per day) reduces tumor growth in an H146 small cell lung cancer mouse xenograft model and induces tumor regression when administered at a dose of 100 mg/kg twice per day. Formulations containing lenvatinib have been used in the treatment of differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.
How to get the best price on Lenvatinib?
Zibo Hangyu Biotechnology Development Co., Ltd is a quality supplier and manufacturer of Lenvatinib . You can buy high quality, low price Lenvatinib 417716-92-8 here.
Zibo Hangyu Biotechnology Development Co., Ltd. is a comprehensive chemical enterprise focusing on fine chemical products and pharmaceutical intermediates, integrating research and development, production and sales. The company is equipped with advanced equipment quality inspection and research center. At the same time, the company has excellent talents with rich experience in process development and quality control. To provide customers with total solutions from raw material processing to chemical synthesis systems. The company has established a standardized and perfect quality standard system to provide stable and high quality production and service.
Milestones
- 2012yearThe company was founded, began to engage in the production and supply of chemical raw materials
- 2014yearExpand the scale of production, pharmaceutical raw materials production workshop was established
- 2016yearCooperated with domestic and foreign chemical platforms to promote self-produced and high-end pharmaceutical intermediates
- 2019yearIn recent years to participate in the international pharmaceutical raw materials exhibitions
- 2023yearBusiness continues to expand, Production and Sales teams continue to grow
- 2026yearPlans to set up foreign branches
